Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00043082
First received: August 5, 2002
Last updated: October 23, 2015
Last verified: October 2015